"Here on the left-hand side of the chart, you see 2 examples. In dermatology, we continue to see patient visits and NBRx below the pre-pandemic levels. In the bottom, you can see, in the oncology markets, depending on the cancer setting, you have biopsy and surgery rates below pre-pandemic levels, also in the CDK4/6 market."